New York, New York-- (Newsfile Corp. - March 13, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against TransMedics Group, Inc. (NASDAQ: TMDX) ...

TransMedics Group (NASDAQ:TMDX – Get Free Report)‘s stock had its “buy” rating restated by Canaccord Genuity Group in a ...

It's been a rough several months for TransMedics Group (NASDAQ: TMDX) shareholders. The stock has been beaten down by about ...

TransMedics is revolutionizing organ transplant therapy with its FDA-approved Organ Care System. See why I rate TMDX stock as a buy.

NEW YORK, March 10, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against TransMedics Group, Inc. (NASDAQ: TMDX ...

TransMedics' strong Q4 performance and market share growth signal a promising future for investors. Click here to find out ...

LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against TransMedics Group, Inc. (“TransMedics” or “the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

TransMedics Group Inc (TMDX) reports a robust 50% year-over-year revenue growth, improved profitability, and strategic ...

TransMedics Group (NASDAQ:TMDX – Get Free Report) will likely be announcing its earnings results after the market closes on Thursday, February 27th. Analysts expect the company to announce earnings of ...

TransMedics (TMDX) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.12 per share a year ago.